CA AB2531

Repeals the ban on compensating women who provide human oocytes for medical research; compensation amounts to be determined by institutional review boards or human subject research panels, similar to other research subjects.

Requires institutional review boards to inform research subjects that ongoing studies will continue to assess long-term health impacts of ovarian stimulation and oocyte retrieval procedures.

Mandates that research programs offering compensation for oocyte donation comply with existing protections including informed consent, medical screening, post-procedure examinations, and coverage for any resulting medical expenses at no cost to the subject.

Allows institutional review boards to disregard compensation amounts when women undergoing fertility treatment donate excess oocytes or embryos for research, provided specific conditions are met including that the donation does not compromise the woman's fertility treatment.